Senseonics Holdings Inc(SENS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:59 PM ET (Korea 10/29 05:59)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.28 | Insider Own | 11.93% | Shs Outstand | 52.9M | Perf Week | 17.19% |
| Market Cap | 0.49B | Forward P/E | - | EPS next Y | 15.63% | Insider Trans | 0.58% | Shs Float | 46.6M | Perf Month | -7.06% |
| Enterprise Value | 0.41B | PEG | - | EPS next Q | -0.52 | Inst Own | 39.64% | Short Float | 10.46% | Perf Quarter | 84.22% |
| Income | -0.11B | P/S | 10.17 | EPS this Y | -37.51% | Inst Trans | 29.19% | Short Ratio | 7.01 | Perf Half Y | 45.37% |
| Sales | 0.05B | P/B | 5.47 | EPS next 5Y | 2.71% | ROA | -66.88% | Short Interest | 4.87M | Perf YTD | 69.2% |
| Book/sh | 1.71 | P/C | 3.45 | EPS past 3/5Y | 8.64% 35.96% | ROE | -118.24% | 52W High | -12.22% ($10.64) | Perf Year | 29.72% |
| Cash/sh | 2.7 | P/FCF | - | Sales past 3/5Y | 29.09% 48.1% | ROIC | -71.89% | 52W Low | 94.99% ($4.79) | Perf 3Y | -3.11% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -11.42% | Gross Margin | 54.87% | Volatility(W/M) | 9.57% 6.37% | Perf 5Y | -86.81% |
| Dividend TTM | - | EV/Sales | 8.52 | Sales Y/Y TTM | 90.63% | Oper. Margin | -223.22% | ATR (14) | 0.56 | Perf 10Y | -80.38% |
| Dividend Ex-Date | - | Quick Ratio | 6.4 | EPS Q/Q | -77.96% | Profit Margin | -225.34% | RSI (14) | 57.47 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.74 | Sales Q/Q | 117.82% | SMA20 | 7.49% ($8.69) | Beta | 1.04 | Target Price | $13.67 |
| Payout | - | Debt/Eq | 0.7 | Earnings | 2026/11/9 | SMA50 | 1.96% ($9.16) | Rel Volume | 1.44 | Prev Close | $8.33 |
| Employees | 130 | LT Debt/Eq | 0.68 | EPS/Sales Surpr. | -2.84% 8.61% | SMA200 | 30.11% ($7.18) | Avg Volume(3M) | 0.69M | Price | $9.34 |
| IPO | 2015/12/22 | Option/Short | Yes/Yes | Trades | 8218 | Volume | 998,944 | Change | 12.12% |
🩺 An innovative medical device company developing long-term implantable continuous glucose monitoring (CGM) systems for diabetes patients. It commercializes the Eversense system, which can be used for up to one year through subcutaneous implantation, offering a new alternative in a market previously dominated by short-term wearable devices.
Over the past 1 year, on the higher side
12% below its 1-year high.
Traded more than usual. That is 144% of its average volume.
Next earnings report: November 9
11 days to go.
SENS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -37.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,017. Peers typically go for $343. Compared with its own 1-year average, it is 84% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -86.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 39.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #58 of 142 in the industry
Based on market cap of $494M.
DCTH#56 Delcath Systems Inc $516M PER 2436.1 
SGHT#57 Sight Sciences Inc $509M PER - SENS#58 Senseonics Holdings Inc $494M PER - 
SSII#59 SS Innovations International Inc $489M PER - 
CERS#60 Cerus Corp $488M PER - 
FAQ
What kind of company is SENS?
SENS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of SENS?
The market cap of SENS is approximately $494M, ranking 3,170 within its sector.
What is the 52-week high and low for SENS?
SENS has recorded a 52-week high of $10.64 and a low of $4.79.
